Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives

There is an increasing clinical interest in the measure and achievement of minimal residual disease (MRD) negativity in the bone marrow of Multiple Myeloma (MM) patients, as defined equally either by Multicolor Flow Cytometry (MFC) or by Next Generation Sequencing (NGS) technologies. At present, mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Romano, Alessandra, Palumbo, Giuseppe Alberto, Parrinello, Nunziatina Laura, Conticello, Concetta, Martello, Marina, Terragna, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710454/
https://www.ncbi.nlm.nih.gov/pubmed/31482061
http://dx.doi.org/10.3389/fonc.2019.00699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710454/
https://www.ncbi.nlm.nih.gov/pubmed/31482061
http://dx.doi.org/10.3389/fonc.2019.00699

Ejemplares similares